• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Issues that matter
    • COVID-19 in India
    • Inadequate safe drinking water
    • Poor sanitation
    • Environmental health
    • Infectious disease
      • Hepatitis C
    • Noncommunicable Diseases (NCDs)
    • Malnutrition
    • High infant mortality
    • Mental health
    • Sex and gender discrimination
  • Special Focus
    • Interviews
      • Exclusive Interviews
      • Readers Interviews
    • Vaccine Hesitancy
  • News
  • PandemiCast
  • Partner’s Press Office

Health Issues India

Health issues in India

  • Home
  • About Us
  • Editorial Team
  • Subscribe
  • Contribute
  • Sponsor
  • Contact Us
You are here: Home / Featured / WHO weighs in on India’s Kala-Azar situation

WHO weighs in on India’s Kala-Azar situation

July 6, 2021 By Nicholas Parry Leave a Comment

The World Health Organization (WHO) has issued a report regarding India’s continued fight against visceral leishmaniasis — also known as kala-azar (KA).

Copyright: drmicrobe / 123RF Stock Photo kala-azar
Cutaneous leishmaniasis ulcer and close-up view of leishmania promastigotes

Overall, the report praises India’s National Kala-Azar Elimination Programme (NKEP), noting the “the Government of India is committed to eliminating KA as a public health problem, and continued political, administrative, technical and partner support have put India on the verge of achieving the elimination target in 2021. Covering the last mile of elimination is therefore the main task of the NKEP.” 

However, the situation regarding kala-azar in India is rife with mixed messages. On one hand, the disease is likely one of the closest to being considered eliminated in India, with the vast majority of areas in which the disease is prevalent already qualifying for the status of elimination — though, critically, not eradication. In sharp contrast to the optimism of the disease being close to elimination is the fact that this has been the case for more than a decade.

As Health Issues India reported at the time of the Union Health Budget 2017, “despite being the most likely to be eliminated, this target has been set and was not attained in previous announcements by the Indian government. In 2014…Health Minister Harsh Vardhan claimed the disease would be eliminated by 2015. Previous deadlines had been set for 2010.”

The distribution of kala-azar has been broken down by the WHO as follows; “cutaneous leishmaniasis is confined to the north-western part of the country ([Himachal] Pradesh, Rajasthan), whereas KA is endemic in four states, Bihar (33 districts, 458 blocks), Jharkhand (four districts, 33 blocks), West Bengal (eleven districts, 120 blocks) and Uttar Pradesh (six districts, 22 blocks), which contain approximately ten percent of the total population at risk in India (136.5 million). In Uttar Pradesh, five more districts are categorised as previously endemic. A few sporadic and imported cases are reported in other parts of [the] country (Assam, Delhi, Kerala, Sikkim, Tamil Nadu and Uttarakhand).”

“There are around 130 million people at risk of kala-azar in the 54 districts of four endemic States,” said Dr Neeraj Dhingra, director of the National Vector Borne Disease Control Programme at the Union Ministry of Health and Family Welfare, in a previous WHO report. “We have made substantial progress in reducing the endemicity of kala-azar by ensuring house to house search, treatment and follow up of cases. We are determined to eliminate the disease soon and counter the challenges of continued transmission in the country.”

Cases above the elimination threshold are now restricted to just six percent of districts. While effective treatment is available, detection is where India is falling behind. “…We’ve had weak reporting of relapsed cases, increased cases of post Kala-azar dermal leishmaniasis and inadequate tools for vector surveillance. All these need to be addressed along with a reinforcement of the national task force to harmonise efforts by stakeholders and the ministry of health” said Dr Jorge Alvar, head of the mission who, in the past, led the global leishmaniasis elimination programme at the WHO.

The disease has shown to be easily treated, with clinical trials of amphotericin B showing an efficacy of around 99 percent. In order to actually move towards eradicating the diseases, however, India will need to mobilise a greater surveillance network, alongside a rollout of the medication.

India’s NKEP has shown a huge degree of success in reducing disease cases as a result of the availability of effective treatment. According to the report, “the number of KA cases has decreased by 97 percent (2,048 cases in 2020) since the start of intensified KA activities in 1992 (77,102 cases), and the number of deaths has been reduced from 1,419 in 1992 to 58 in 2018 and further decreases to 43 in 2019 and 37 in 2020 (provisional).” 

The WHO report noted that “the [NKEP] must overcome operational challenges such as the quality of surveillance, IRS operations and engagement of private and rural health practitioners. The COVID-19 pandemic has affected programme implementation since early 2020; however, essential case management and vector control activities have been resumed. The impact of COVID-19 on NKEP is yet to be assessed.”

As with many other diseases kala-azar may have fallen into a lower priority placement during the COVID-19 pandemic. Lack of surveillance during this time could allow for the disease to resurge and reclassify more districts into the above-elimination levels. Kala-azar is a perfect demonstration that when it comes to the eradication of diseases, it is often the final hurdle that proves to be the most difficult.

Filed Under: Featured, Government policy, Infectious diseases, National, News Tagged With: Kala-azar, visceral leishmaniasis

About Nicholas Parry

Nicholas Parry has a Bachelor of Science in genetics from the University of Sheffield and a Master of Research in neuroscience from the University of Nottingham. He has been a featured writer for Health Issues since 2016. He is based in South Wales.

Reader Interactions

Leave a Reply Cancel reply

You must be logged in to post a comment.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Articles

  • Renewed fears of a bird flu pandemic; The latest health stories from around the world
  • More oversight needed for “gain of function” research says expert panel; The latest health stories from around the world
  • Marion Biotech to be investigated by Indian drug regulator
  • Sesame to be added to list of major food allergens
  • Approval of Alzheimer’s drug “rife with irregularities”

Footer

Archives

Issues that matter

  • Environmental health
  • Inadequate safe drinking water
  • Poor sanitation
  • Infectious disease
  • Noncommunicable Diseases (NCDs)
  • Malnutrition
  • High infant mortality

Categories

Copyright © 2023 · News Pro On Genesis Framework · WordPress · Log in

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
Cookie settingsACCEPTACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.